Press Releases Cingulate Inc.

Equities

CING

US17248W2044

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-09 pm EDT			5-day change	1st Jan Change
0.885 ^USD	-0.34%		-20.98%	-88.43%

May. 08	Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Certain Pre-Funded Warrants of Cingulate Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update	May. 08	AQ
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access	Apr. 30	AQ
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024	Apr. 16	AQ
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update	Apr. 01	AQ
Cingulate to Participate in Benzinga All Live Access Event	Mar. 19	AQ
Cingulate to Attend DCAT Week 2024 in New York City	Mar. 06	AQ
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors	Feb. 13	AQ
Cingulate Announces Closing of $7.5 Million Public Offering	Feb. 06	AQ
Cingulate Announces Pricing of $7.5 Million Public Offering	Feb. 02	AQ
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO	Jan. 29	AQ
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market	Jan. 29	AQ
Cingulate : Failure to Satisfy Listing Rule - Form 8-K	Dec. 28	PU
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)	Dec. 04	AQ
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)	Dec. 01	AQ
Cingulate : Failure to Satisfy Listing Rule - Form 8-K	Nov. 14	PU
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update	Nov. 13	AQ
Cingulate to Host CNS Key Opinion Leader Panel in New York City	23-10-17	AQ
Cingulate Inc. To Present at the LD Micro Main Event XVI	23-09-21	NE
Cingulate Announces Closing of $4.0 Million Public Offering	23-09-13	AQ
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 for ADHD	23-09-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cingulate Inc.

Equities

CING

US17248W2044

Press Releases

Filters